These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 34351091)

  • 1. Humoral response to SARS-CoV-2 vaccination promises to improve the catastrophic prognosis of hemodialysis patients as a result of COVID-19: the COViNEPH Project.
    Tylicki L; Biedunkiewicz B; Dąbrowska M; Ślizień W; Tylicki P; Polewska K; Rosenberg I; Rodak S; Dębska-Ślizień A
    Pol Arch Intern Med; 2021 Sep; 131(9):797-801. PubMed ID: 34351091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study.
    Lesny P; Anderson M; Cloherty G; Stec M; Haase-Fielitz A; Haarhaus M; Santos C; Lucas C; Macario F; Haase M
    J Nephrol; 2021 Aug; 34(4):975-983. PubMed ID: 34050904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
    Casas Fischer R
    Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.
    Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S
    Front Immunol; 2022; 13():876533. PubMed ID: 35711413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with anti-SARS-CoV-2 spike antibody titers after a second BNT162b2 mRNA COVID-19 vaccination in Japanese hemodialysis patients.
    Hirai K; Shimotashiro M; Sonoda T; Okumura T; Ookawara S; Morishita Y
    Clin Exp Nephrol; 2022 Sep; 26(9):925-932. PubMed ID: 35426594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2.
    Speer C; Göth D; Benning L; Buylaert M; Schaier M; Grenz J; Nusshag C; Kälble F; Kreysing M; Reichel P; Töllner M; Hidmark A; Ponath G; Schnitzler P; Zeier M; Süsal C; Morath C; Klein K
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1073-1082. PubMed ID: 34031181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to and outcomes of the Pfizer BNT162B2 vaccine in hemodialysis patients-A prospective observational study.
    Al-Muhaiteeb A; AlSahow A; Al-Yousef A; AlHelal B; Alrajab H; Bahbahani Y; Dewidar N; Fanous GNM
    Hemodial Int; 2022 Apr; 26(2):216-222. PubMed ID: 34989097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis.
    Grupper A; Sharon N; Finn T; Cohen R; Israel M; Agbaria A; Rechavi Y; Schwartz IF; Schwartz D; Lellouch Y; Shashar M
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1037-1042. PubMed ID: 33824157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors predictive of anti-spike antibody titers after COVID-19 vaccination in hemodialysis patients.
    Aoun M; Kahwaji RM; Sleilaty G; Boueri C; Hawi J; Khalil CB; Hage V
    Adv Clin Exp Med; 2022 Aug; 31(8):855-861. PubMed ID: 35438849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination.
    Gonzalez-Perez M; Montes-Casado M; Conde P; Cervera I; Baranda J; Berges-Buxeda MJ; Perez-Olmeda M; Sanchez-Tarjuelo R; Utrero-Rico A; Lozano-Ojalvo D; Torre D; Schwarz M; Guccione E; Camara C; Llópez-Carratalá MR; Gonzalez-Parra E; Portoles P; Ortiz A; Portoles J; Ochando J
    Front Immunol; 2022; 13():845882. PubMed ID: 35401504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan.
    Kanai D; Wakui H; Haze T; Azushima K; Kinguchi S; Tsukamoto S; Kanaoka T; Urate S; Toya Y; Hirawa N; Kato H; Watanabe F; Hanaoka K; Hanaoka M; Mitsuhashi H; Yamaguchi S; Ohnishi T; Tamura K
    Clin Exp Nephrol; 2022 Oct; 26(10):988-996. PubMed ID: 35751753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis.
    Kanai D; Wakui H; Hanaoka M; Haze T; Azushima K; Shinoda S; Tsukamoto S; Taguchi S; Kinguchi S; Kanaoka T; Toya Y; Hirawa N; Kato H; Watanabe F; Hanaoka K; Mitsuhashi H; Yamaguchi S; Ohnishi T; Tamura K
    Clin Exp Nephrol; 2023 Jul; 27(7):639-647. PubMed ID: 36977892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals.
    Hayer J; Urlaub E
    Microbiol Spectr; 2022 Jun; 10(3):e0270921. PubMed ID: 35575594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
    Bensouna I; Caudwell V; Kubab S; Acquaviva S; Pardon A; Vittoz N; Bozman DF; Hanafi L; Faucon AL; Housset P
    Am J Kidney Dis; 2022 Feb; 79(2):185-192.e1. PubMed ID: 34508833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients.
    Danthu C; Hantz S; Dahlem A; Duval M; Ba B; Guibbert M; El Ouafi Z; Ponsard S; Berrahal I; Achard JM; Bocquentin F; Allot V; Rerolle JP; Alain S; Touré F
    J Am Soc Nephrol; 2021 Sep; 32(9):2153-2158. PubMed ID: 34135083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A third dose SARS‑CoV‑2 BNT162b2 mRNA vaccine results in improved immune response in hemodialysis patients.
    Melin J; Svensson MK; Albinsson B; Winqvist O; Pauksens K
    Ups J Med Sci; 2022; 127():. PubMed ID: 36337280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical Stepwise Decline of Antibodies against SARS-CoV-2 among Chronic Hemodialysis Patients 180 Days Post Comirnaty Vaccine.
    Levin-Iaina N; Angel-Korman A; Leiba A; Peres E; Bryk G; Rapoport V; Katzir Z; Yagil Y; Brosh-Nissimov T
    Isr Med Assoc J; 2022 May; 24(5):317-319. PubMed ID: 35598056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.